Derek L. Buhl, PhD, is the scientific director of AbbVie. With over a decade of experience in the industry, Buhl is responsible for the translational strategy for CNS disorders in late-stage discovery and across clinical development stages, first-in-human, proof-of-mechanism, proof-of-concept, registration studies as well as life cycle management studies. He earned his bachelor’s degrees in psychology and a PhD in neuroscience from Rutgers University-Newark.

We recently redesigned the Neuronline website - as a result, some pages were moved or changed. Try looking in the appropriate section above, or using the search box at the upper right.